Why physicians are turning to gold to cure rare diseases...

You are receiving this email as a part of your subscription to Strategic Tech Investor. It's important to whitelist our email address, customerservice@strategictechinvestor.com, for you to continue receiving Strategic Tech Investor. Your ability to alter your subscription information can be found at the bottom of this email.

Dear Reader, As part of your subscription to Strategic Tech Investor, we will cover major advancements in Silicon Valley tech... legal marijuana... cryptocurrencies... and biotechnology. Of course, beyond showing those innovations, there is a way to "play" them - to invest in them... and potentially pocket massive gains... See for yourself, below are just a few of the peak gains that the team and I here have shown readers over the years: 818% on Pharmacyclics... 629% on Celldex... 396% on NetQin... 314% on FleetCor Technologies... 543% on Westport Innovations... 361% on Inovio... 504% on Gilead, and... 345% on Aegerion. And I just saw a biotech advancement so exciting that I have to share it with you right away. Soon, we might be able to use gold - yes, the yellow metal we all covet to one degree or another - to "edit" our brains. Honestly, I barely believed it myself when I saw it, but the plain truth is this... Gold is the key to curing neurological disorders, epilepsy, chronic pain, addiction, and even rare diseases like Huntington's. It's also proven to help alleviate some of the symptoms associated with autism. It's not a cure, but it's true - gold could be the answer for hundreds of thousands of people worldwide who are suffering with these ailments. With more than 30 years in the technology sector, I can easily say that this is one of the most disruptive and exciting innovations I've seen to date. Here is your first look at this revolutionary investment opportunity that could bring BIG PHARMA to its knees, all while sparking a potential 28,700% revenue surge in the next few months. Click here to learn more. Until tomorrow... Cheers and good investing, Michael A. Robinson Share Strategic Tech Investor: You are receiving this e-mail at, ITS028@gmail.com, as a part of your free subscription to Strategic Tech Investor. Remove your email from this list: Unsubscribe To cancel by mail or for any other subscription issues, write us at: Strategic Tech Investor | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 Contact Customer Service Website: https://strategictechinvestor.com © 2019 Strategic Tech Investor All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Strategic Tech Investor. 1125 N Charles Street, Baltimore, MD 21201.